132 Views
Sunday Poster Session
Category: IBD
Kenneth Leung, MD
University of California Riverside School of Medicine
San Bernardino, CA, United States
Age (y), median (range) | 71 (60-84) |
Gender |
|
Male | 91 (98%) |
Female | 3 (3%) |
Ethnic/Racial Background |
|
White | 70 (75%) |
African American | 7 (8%) |
Hispanic | 4 (4%) |
Asian | 1 (1%) |
Other | 2 (2%) |
Unknown | 10 (11%) |
Type of IBD |
|
Ulcerative colitis | 57 (61%) |
Crohn’s disease | 31 (33%) |
Indeterminate | 6 (6%) |
Disease duration (y), median (range) | 14 (1-54) |
Location (Ulcerative colitis) |
|
Proctitis (E1) | 2 (4%) |
Left sided (E2) | 20 (35%) |
Extensive colitis (E3) | 24 (42%) |
Unknown | 11 (19%) |
Location (Crohn’s disease) |
|
Ileal (L1) | 8 (26%) |
Colonic (L2) | 6 (19%) |
Ileocolonic (L3) | 15 (48%) |
Unknown | 2 (6%) |
Perianal Disease | 8 (26%) |
Disease status |
|
Active disease | 16 (17%) |
Clinical remission | 78 (83%) |
Previous IBD surgery (Yes) | 14 (15%) |
Current corticosteroid use | 3 (3%) |
Current 5-aminosalicylate use | 40 (43%) |
Current immunomodulator use | 6 (6%) |
Current biologic use | 46 (49%) |
Adalimumab | 9 (20%) |
Infliximab | 4 (9%) |
Vedolizumab | 25 (54%) |
Ustekinumab | 5 (11%) |
Certolizumab | 2 (4%) |
Tofacitinib | 1 (2%) |
Charlson co-morbidity score | 4 (2-10) |
Total number of active medications, median (range) | 9 (0-25) |
Completed licensed clinical social worker visit | 58 (62%) |
Length of visit (mins), median (range) | 25 (10-60) |
PHQ-9 score (≥10) | 7 (12%) |
GAD-7 score (≥10) | 5 (9%) |
Follow-up visit with LCSW | 4 (7%) |